Viropharma (VPHM +4.3%) gets a lift today from a valuation upgrade to Overweight at JPMorgan with a price target of $32 a share. Analyst Brian Abrahams thinks the competitive threats to VPHM's Angioedema treatment Cinryze have been overstated relative to its peers, noting that although some early-stage treatments by its competitors are "worth keeping an eye on," they have characteristics which make them a less-attractive alternative.
Viropharma (VPHM +4.3%) gets a lift today from a valuation upgrade to Overweight at JPMorgan...
From other sites
at CNBC.com (Jun 8, 2015)
at CNBC.com (May 21, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs